<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00336583</url>
  </required_header>
  <id_info>
    <org_study_id>AMC 2006-130</org_study_id>
    <nct_id>NCT00336583</nct_id>
  </id_info>
  <brief_title>Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin as 2nd Line Therapy for Non-Hodgkin's Lymphoma (NHL)</brief_title>
  <official_title>Phase II Study of Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin (ESHAOX) for Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boryung Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oxaliplatin will be used instead of cisplatin in well-known salvage regimen of etoposide,
      methylprednisolone, cytarabine and cisplatin (ESHAP). Clinical efficacy and toxicity of this
      ESHAOX salvage regimen will be evaluated in refractory or relapsed non-Hodgkin's lymphoma
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with aggressive non-Hodgkin's lymphoma (NHL) are known to have a malignancy
      considered curable in many cases. However, diagnosis of refractory or relapsed disease is
      devastating and the treatment is difficult because regimens of chemotherapy used as salvage
      therapy are available only in limited numbers. ESHAP, consisting of etoposide,
      methylprednisolone, high-dose cytarabine and cisplatin, is one of commonly used salvage
      regimen, and showed its efficacy and feasibility. But it often requires discontinuation of
      the treatment due to its myelosuppression, neuropathy and renal toxicity, which can also
      impede further treatment. Oxaliplatin, a platinum coordination complex with an oxalato-ligand
      as the leaving group and a 1,2-diaminocyclohexane carrier, possesses higher cytotoxic potency
      on molar basis than cisplatin and carboplatin, and was reported to be active in patients with
      NHL as a single agent. In addition, the substitution of cisplatin by oxaliplatin in the DHAP
      regimen, another commonly used one in relapsed or refractory NHL, showed meaningful
      anti-tumor activity with favorable toxicity profile. Based on preclinical and clinical
      findings, we will conduct a multi-center phase II study of ESHAOX, which substitutes
      oxaliplatin with cisplatin in the ESHAP regimen, to evaluate the efficacy and toxicity
      profile in patients with recurrent or refractory NHL.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>The Overall Response Rate is measured by the number of patients per the total treatment population who partially or completely responded to treatment. Response will be evaluated according to the International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Worst Toxicity Grade by Patient</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>graded by National Cancer Institute Common Toxicity Criteria of Adeverse Event version 3.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>Oxaliplatin, response</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>relapsed or refractory non-Hodgkin's lymphoma</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Oxaliplatin, 130 mg per square meter, on day 1</description>
    <arm_group_label>Oxaliplatin, response</arm_group_label>
    <other_name>etoposide, 40 mg per square meter on days 1 to 4,</other_name>
    <other_name>methylprednisolone, 500 mg on days 1 to 5,</other_name>
    <other_name>cytarabine, 2 g per square meter on day 5</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Previously histologically confirmed aggressive lymphomas, defined according to WHO
             classification (except Burkitt's lymphoma, lymphoblastic lymphoma)

          -  Failure to achieve a complete remission with the initial induction chemotherapy, or
             recurrent disease

          -  Performance status (ECOG) ≤3

          -  Age ≤ 75

          -  Treated with at least one CHOP or CHOP-derived doxorubicin containing regimen

          -  At least one or more uni-dimensionally measurable lesion(s) defined as; ≥2 cm by
             conventional CT or ≥ 1 cm by spiral CT or skin lesion (photographs should be taken) or
             measurable lesion by physical examination

          -  Adequate organ functions defined as; ANC &gt; 1,500/ul, platelet &gt; 75,000/ul,
             transaminases &lt; 3 X upper normal values; bilirubin &lt; 2 mg%

          -  Written informed consent approved by Institutional Review Board

        Exclusion Criteria:

          -  Any other malignancies within the past 5 years except skin basal cell ca or CIS of
             cervix

          -  Serious co-morbid diseases

          -  Pregnancy or breast-feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cheolwon Suh, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <results_reference>
    <citation>Sym SJ, Lee DH, Kang HJ, Nam SH, Kim HY, Kim SJ, Eom HS, Kim WS, Suh C. A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin's lymphoma. Cancer Chemother Pharmacol. 2009 Jun;64(1):27-33. doi: 10.1007/s00280-008-0847-y. Epub 2008 Oct 7.</citation>
    <PMID>18839172</PMID>
  </results_reference>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2006</study_first_submitted>
  <study_first_submitted_qc>June 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2006</study_first_posted>
  <results_first_submitted>May 5, 2009</results_first_submitted>
  <results_first_submitted_qc>May 25, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 22, 2010</results_first_posted>
  <last_update_submitted>May 25, 2010</last_update_submitted>
  <last_update_submitted_qc>May 25, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2010</last_update_posted>
  <responsible_party>
    <name_title>Suh, Cheolwon</name_title>
    <organization>AsanMedical Center, University of Ulsan College of Medicine</organization>
  </responsible_party>
  <keyword>oxaliplatin</keyword>
  <keyword>ESHAOX</keyword>
  <keyword>refractory</keyword>
  <keyword>relapsed</keyword>
  <keyword>non-hodgkin's lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 27 patients were enrolled between April and December 2006 from eight institutions in South Korea.</recruitment_details>
      <pre_assignment_details>Patients with symptomatic central nervous system involvement and pregnant or breastfeeding women were excluded. Patients with grade 2 or more peripheral neuropathy at the time of study entry were also excluded.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ESHAOx</title>
          <description>The ESHAOx consisted of Etoposide (40 mg per square meter on days 1–4), Methylprednisolone (500 mg on days 1–5), Cytarabine (2 g per square meter on day 5), and Oxaliplatin (130 mg per square meter on day 1) every 3 weeks to a maximum of six cycles.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ESHAOx</title>
          <description>The ESHAOx consisted of Etoposide (40 mg per square meter on days 1–4), Methylprednisolone (500 mg on days 1–5), Cytarabine (2 g per square meter on day 5), and Oxaliplatin (130 mg per square meter on day 1) every 3 weeks to a maximum of six cycles.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.2" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Response Rate</title>
        <description>The Overall Response Rate is measured by the number of patients per the total treatment population who partially or completely responded to treatment. Response will be evaluated according to the International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas.</description>
        <time_frame>up to 24 weeks</time_frame>
        <population>25 patients who had complete at least 3 cycles of ESHAOx study treatment were analyzed. 2 patients who did not completed 3 cylces of study treatment were excluded from the response analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>ESHAOx</title>
            <description>The ESHAOx consisted of Etoposide (40 mg per square meter on days 1–4), Methylprednisolone (500 mg on days 1–5), Cytarabine (2 g per square meter on day 5), and Oxaliplatin (130 mg per square meter on day 1) every 3 weeks to a maximum of six cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate</title>
          <description>The Overall Response Rate is measured by the number of patients per the total treatment population who partially or completely responded to treatment. Response will be evaluated according to the International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas.</description>
          <population>25 patients who had complete at least 3 cycles of ESHAOx study treatment were analyzed. 2 patients who did not completed 3 cylces of study treatment were excluded from the response analysis.</population>
          <units>pariticipants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Worst Toxicity Grade by Patient</title>
        <description>graded by National Cancer Institute Common Toxicity Criteria of Adeverse Event version 3.0</description>
        <time_frame>up to 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ESHAOx</title>
            <description>The ESHAOx consisted of Etoposide (40 mg per square meter on days 1–4), Methylprednisolone (500 mg on days 1–5), Cytarabine (2 g per square meter on day 5), and Oxaliplatin (130 mg per square meter on day 1) every 3 weeks to a maximum of six cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Worst Toxicity Grade by Patient</title>
          <description>graded by National Cancer Institute Common Toxicity Criteria of Adeverse Event version 3.0</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 3 or 4 neutropenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 or 4 thrombocytopenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>9 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ESHAOx</title>
          <description>The ESHAOx consisted of Etoposide (40 mg per square meter on days 1–4), Methylprednisolone (500 mg on days 1–5), Cytarabine (2 g per square meter on day 5), and Oxaliplatin (130 mg per square meter on day 1) every 3 weeks to a maximum of six cycles.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>thrombocytopenia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>leukopenia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Cheolwon Suh</name_or_title>
      <organization>Asan Medical Center</organization>
      <phone>82 2 3010 3209</phone>
      <email>csuh@amc.seoul.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

